The goal of this activity is to improve participants’ competence in implementing the most recent guideline changes and clinical advances in the management of patients with indolent non-Hodgkin’s lymphomas.

This information was originally presented on March 13, 2014, at the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

Join Anas Younes, MD, and Andrew Zelenetz, MD, PhD, as they present their multidisciplinary expertise on a range of cases pertaining to follicular lymphoma.

Join Anas Younes, MD, and Andrew Zelenetz, MD, PhD, as they present their multidisciplinary expertise on a range of cases pertaining to follicular lymphoma.

This information was originally presented on September 21, 2013, at the NCCN 8^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 21, 2013, at the NCCN 8^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 21, 2013, at the NCCN 8^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

There is a need for clinicians to evaluate available data from recent clinical trials and to incorporate new findings to the management of their older patient population, as appropriate.

In order for patients to derive the most benefit from post-remission strategies, the need exists for physicians to critically evaluate available data from recent clinical trials and to identify the appropriate candidates for incorporating such strategies.

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin’s Lymphoma (NHL) and provide a discussion of the clinical evidence that support the updates.